Literature DB >> 2458560

A normal ultrasound does not obviate the need for amniocentesis in patients with elevated serum alpha-fetoprotein.

A Drugan1, I E Zador, F N Syner, R J Sokol, A J Sacks, M I Evans.   

Abstract

Elevated levels of maternal serum alpha-fetoprotein (MSAFP) will identify a population at increased risk for specific congenital malformations, which are accurately diagnosed by amniotic fluid AFP and acetylcholinesterase. The risk for spontaneous abortion related to amniocentesis, combined with increasing confidence in the accuracy of ultrasound diagnosis, has caused us to question the need for amniocentesis in the diagnostic workup of pregnancies complicated by elevated levels of AFP in maternal serum. A retrospective study of 257 pregnancies evaluated for elevated serum AFP levels revealed 16 fetal malformations diagnosed by amniotic fluid AFP and acetylcholinesterase. Only 12 of these malformations were diagnosed on the initial ultrasound study. All malformations were diagnosed when ultrasound examination was repeated for increased acetylcholinesterase activity. Earlier gestational age at scanning, smaller defects, and pure technical failure were implicated as causes of misdiagnosis. The rate of fetal malformations identified in this high-risk population (6.23%) and the rate of ultrasound misdiagnosis (1.5% of the population with elevated levels of MSAFP) imply that amniocentesis should still be considered an essential part of the diagnostic workup in these situations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458560

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

Review 1.  Fetal ultrasonography.

Authors:  S H Garmel; M E D'Alton
Journal:  West J Med       Date:  1993-09

2.  Prenatal screening: when and for whom?

Authors:  N A Holtzman
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

3.  Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  CMAJ       Date:  1994-07-15       Impact factor: 8.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.